Day One Biopharmaceuticals Inc (DAWN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Day One Biopharmaceuticals Inc (DAWN) has a cash flow conversion efficiency ratio of -0.013x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.80 Million) by net assets ($450.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DAWN equity to assets ratio to measure how much of total assets are equity-financed.
Day One Biopharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Day One Biopharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Day One Biopharmaceuticals Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Day One Biopharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Day One Biopharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xi'an Sinofuse Electric Co. Ltd.
SHE:301031
|
N/A |
|
Bombay Burmah Trading Corporation Limited
NSE:BBTC
|
0.039x |
|
Playtech plc
F:PL8
|
0.082x |
|
Nokian Renkaat Oyj
HE:TYRES
|
0.015x |
|
Shandong Denghai Seeds Co Ltd
SHE:002041
|
0.070x |
|
M. Dias Branco S.A. Indústria e Comércio de Alimentos
SA:MDIA3
|
0.023x |
|
Darbond Technology Co. Ltd. A
SHG:688035
|
N/A |
|
CSG Holding Co Ltd
SHE:000012
|
0.033x |
Annual Cash Flow Conversion Efficiency for Day One Biopharmaceuticals Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Day One Biopharmaceuticals Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see DAWN market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $502.75 Million | $-78.11 Million | -0.155x | +63.34% |
| 2023-12-31 | $346.54 Million | $-146.85 Million | -0.424x | -28.06% |
| 2022-12-31 | $332.04 Million | $-109.87 Million | -0.331x | -91.67% |
| 2021-12-31 | $281.15 Million | $-48.54 Million | -0.173x | +44.37% |
| 2020-12-31 | $43.46 Million | $-13.49 Million | -0.310x | -135.65% |
| 2019-12-31 | $-5.19 Million | $-4.51 Million | 0.871x | -- |
About Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory… Read more